Showing 1891-1900 of 2652 results for "".
- Regenxbio Announces Lancet Publication of Phase 1/2a Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMDhttps://modernod.com/news/regenxbio-announces-lancet-publication-of-phase-12a-study-evaluating-abbv-rgx-314-as-a-one-time-gene-therapy-for-wet-amd/2482186/Regenxbio announced the publication of results from the phase 1/2a trial evaluating the safety and tolerability of a single dose of subretinal ABBV-RGX-314 for the treatment of wet age-related macular degeneration (AMD). Two-year data were
- Signs of Glaucoma May Be Detectable Years in Advance of Disease Onsethttps://modernod.com/news/nih-signs-of-glaucoma-may-be-detectable-years-in-advance-of-disease-onset/2481989/Research funded by the National Eye Institute suggests that low density of pigment in the macula, the region of the retina required for sharp central vision, is associated with thinning of the retina and may serve as an early warning sign of glaucoma. The findings are based on nearly 400 women wh
- Adverum’s Ixo-Vec for Wet AMD Evaluated in 3-Year Data from OPTIC Extension Studyhttps://modernod.com/news/adverums-ixo-vec-for-wet-amd-evaluated-in-3-year-data-from-optic-extension-study/2481951/Adverum Biotechnologies announced updated data from the OPTIC extension study of patients with wet age-related macular degeneration (AMD) and a summary of previously announced aflibercept protein levels from the LUNA study were presented during the Retina Subspecialty Day at AAO 2023 in
- GATHER2 Study Shows Izervay Monthly or Every Other Month Reduced GA Lesion Growth Through 2 Yearshttps://modernod.com/news/gather2-study-shows-izervay-monthly-or-every-other-month-reduced-ga-lesion-growth-through-2-years/2481944/Astellas Pharma announced results from the GATHER2 phase 3 clinical trial, demonstrating Izervay (avacincaptad pegol intravitreal solution) continued to reduce the rate of geographic atrophy (GA) lesion growth for both every month (EM) and every-other-month (EOM) dosing vs. sham through
- Sight Sciences Announces New MIGS Data Demonstrating TCOR Using OMNI Surgical System Lowers IOP and Medication Use at 2 Yearshttps://modernod.com/news/sight-sciences-announces-new-migs-data-demonstrating-tcor-using-omni-surgical-system-lowers-iop-and-iop-reducing-medications-at-2-years/2481863/Sight Sciences announced the results of the large scale, comparative real-world clinical outcomes study of patients treated by three leading minimally invasive glaucoma surgery (MIGS) technologies, which were recently presented at the 41st Congress of the European Society of Cataract an
- Lumibird Medical Renames its Polish Subsidiary to Lumibird Medical Polskahttps://modernod.com/news/lumibird-medical-renames-its-polish-subsidiary-to-lumibird-medical-polska/2481613/Lumibird Medical Group has renamed its Polish subsidiary, Quantel Medical Polska, to Lumibird Medical Polska. After 5 years of existence, the Polish subsidiary, with a constant double-digit growth since its creation, has moved to a larger site in Warsaw. “
- International Sports Vision Association Announces Leadership Appointments OF NEW EXECUTIVE AND ADVISORY BOARD OFFICERShttps://modernod.com/news/international-sports-vision-association-announces-leadership-appointments-of-new-executive-and-advisory-board-officers/2481491/The International Sports Vision Association (ISVA) announced the appointments of its new Executive and Advisory Board members, effective April 1, 2023. Executive Board Alireza Somji, OD assumes the position of President, succeeding Charles Shidlofsky, OD, FCOV
- Ophtec Celebrates 40 Year Anniversary with New Brand Identityhttps://modernod.com/news/ophtec-celebrates-40-year-anniversary-with-new-brand-identity/2481460/Ophtec is celebrating its 40th anniversary in 2023 and launching a new brand identity, "Modernized and fit for the future." Ophtec was founded in 1983 by the Dutch ophthalmologist Prof. Dr. Jan Worst, also known as the inventor of the world’s first Iris fi
- Study: Early Anti-VEGF Treatment of Diabetic Retinopathy Slows Progression but Yields No Benefit to Visual Acuityhttps://modernod.com/news/study-early-anti-vegf-treatment-of-diabetic-retinopathy-slows-progression-but-yields-no-benefit-to-visual-acuity/2481399/While early treatment of diabetes-related eye disease slowed progression to severe disease, it did not improve visual acuity compared with treating more severe disease once it developed, according to a clinical study from the DRCR Retina Network. The study was funded by the National Eye Institute
- Eyenovia Announces Promotion of Bren Kern to Chief Operating Officer and Corporate Vice Presidenthttps://modernod.com/news/eyenovia-announces-promotion-of-bren-kern-to-chief-operating-officer-and-corporate-vice-president/2481283/Eyenovia announced that Bren Kern, who currently serves as Eyenovia’s Senior Vice President of Manufacturing and Operations, has been promoted to Chief Operating Officer and Corporate Vice President, effective January 1. “Since joining the company earlier this year, Bren has